Risk stratification in chronic systolic heart failure (HF) is critical to identify the patients who may benefit from advanced therapies. We aimed identifying new biomarkers to improve prognosis evaluation and help to better understand HF physiopathology.
Prognostic evaluation was performed in 198 patients with chronic systolic HF: 99 patients who died from cardiovascular cause within 3 years were individually matched for age, sex, and HF etiology (ischemic vs. not) with 99 patients who were alive after 3 years of HF evaluation. We performed a proteomic profiling of 15 apolipoproteins: Apo-A1, -A2, -A4, -B100, -C1, -C2, -C3, -C4, -D, -E, -F, -H, -J, -L1 and -M using LC-MRM-MS.
In univariate analysis, the levels of Apo-B100 and -L1 were significantly lower and the levels of Apo-C1, -J and -M were significantly higher in patients who died from cardiovascular cause as compared with patients alive. In the final statistical model, Apo-C1, Apo-J and Apo-M improved individually the prediction of cardiovascular death. Ingenuity pathway analysis indicated these 3 Apo in a network associated with lipid metabolism, atherosclerosis signaling and RXR activation.
Proteomic profiling of apolipoproteins using LC-MRM-MS might be useful in clinical practice for risk stratification of HF patients. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

Author